Your browser doesn't support javascript.
loading
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato, Taigo; Matsubara, Nobuaki; Shiota, Masaki; Eto, Masatoshi; Osawa, Takahiro; Abe, Takashige; Shinohara, Nobuo; Yasumizu, Yota; Tanaka, Nobuyuki; Oya, Mototsugu; Nishimoto, Koshiro; Hayashi, Takuji; Nakayama, Masashi; Kojima, Takahiro; Namikawa, Kenjiro; Fujisawa, Takao; Okano, Susumu; Hida, Eisuke; Nakamura, Yoshiaki; Bando, Hideaki; Yoshino, Takayuki; Nonomura, Norio.
  • Kato T; Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. kato@uro.med.osaka-u.ac.jp.
  • Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Osawa T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Abe T; Department of Urology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
  • Shinohara N; Department of Urology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
  • Yasumizu Y; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Tanaka N; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Nishimoto K; Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Hayashi T; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakayama M; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Kojima T; Department of Urology, Aichi Cancer Center, Aichi, Japan.
  • Namikawa K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Fujisawa T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Hida E; Department of Biostatistics and Data Science, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Bando H; Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
  • Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Nonomura N; Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
BMC Cancer ; 22(1): 1292, 2022 Dec 09.
Article en En | MEDLINE | ID: mdl-36494792
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article